Reply to "Rituximab versus cyclophosphamide for remission induction in active, severe ANCA-associated vasculitis"

Sharon A. Chung, Philip Seo, Peter A. Merkel, Carol A. Langford

Research output: Contribution to journalComment/debatepeer-review

Abstract

We appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

Original languageEnglish (US)
JournalArthritis and Rheumatology
DOIs
StateAccepted/In press - 2021

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Fingerprint

Dive into the research topics of 'Reply to "Rituximab versus cyclophosphamide for remission induction in active, severe ANCA-associated vasculitis"'. Together they form a unique fingerprint.

Cite this